Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1854)	6/18/1999 6:12:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 2028

More rumbling on the Yahoo thread about sales by insiders. Now Sims and the CFO have dumped shares. My guess is that with the Olsten announcement, the next few Qtrs will be far from "profitable". If you call having $52M in AR profits. This stock will drift down to $5+ again over the next few qtrs. Oxandrin sales were flat for a few months, but have recently picked up slightly. Going forward, BTGC will not be able to "recognize revenue when it ships" since Olsten said they will not take any more for the rest of '99. On top of that, BTGC has no patent protection against a knockoff from a generic company. At the annual meeting, Sims stated that they were working on a way to prevent this from happening. He did not offer a solution to those in attendance. They are waiting to see if the PR over the JAMA weight loss article will actually save face for their overzelous stuffing of the Ox. pipeline. I asked Sims about the $40M increase in AR. Without admitting the obvious, he simply stated that the numbers would improve "significently" in the next few qtrs. Its a gut call -- IMHO profits will be down. Jim